Neogen Corp NEOG
We take great care to ensure that the data presented and summarized in this overview for NEOGEN CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NEOG
View all-
Black Rock Inc. New York, NY24.5MShares$323 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.7MShares$260 Million0.01% of portfolio
-
Select Equity Group, L.P. New York, NY12.6MShares$166 Million0.74% of portfolio
-
Baillie Gifford & CO11.8MShares$155 Million0.15% of portfolio
-
State Street Corp Boston, MA7.56MShares$99.6 Million0.01% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A67.49MShares$98.6 Million0.18% of portfolio
-
Bamco Inc New York, NY7.3MShares$96.2 Million0.31% of portfolio
-
William Blair Investment Management, LLC Chicago, IL7.3MShares$96.1 Million0.31% of portfolio
-
Conestoga Capital Advisors, LLC6.87MShares$90.4 Million1.58% of portfolio
-
Morgan Stanley New York, NY6.76MShares$89 Million0.01% of portfolio
Latest Institutional Activity in NEOG
Top Purchases
Top Sells
About NEOG
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Insider Transactions at NEOG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 25
2024
|
John Edward Adent CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
615
-0.36%
|
$6,765
$11.96 P/Share
|
Apr 25
2024
|
John Edward Adent CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,113
+1.21%
|
$23,243
$11.96 P/Share
|
Apr 25
2024
|
Douglas Edward Jones Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
291
-0.62%
|
$3,201
$11.96 P/Share
|
Apr 25
2024
|
Douglas Edward Jones Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
845
+1.77%
|
$9,295
$11.96 P/Share
|
Apr 25
2024
|
Amy M Rocklin Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
563
+5.11%
|
$6,193
$11.96 P/Share
|
Apr 23
2024
|
John Edward Adent CEO |
BUY
Discretionary transaction
|
Direct |
17,477
+9.33%
|
$209,724
$12.09 P/Share
|
Apr 17
2024
|
Douglas Edward Jones Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+17.82%
|
$120,000
$12.36 P/Share
|
Apr 11
2024
|
James C Borel Director |
BUY
Open market or private purchase
|
Direct |
7,500
+25.96%
|
$97,500
$13.06 P/Share
|
Apr 10
2024
|
David H. Naemura CFO |
BUY
Open market or private purchase
|
Direct |
12,500
+29.38%
|
$150,000
$12.51 P/Share
|
Apr 10
2024
|
John Edward Adent CEO |
BUY
Open market or private purchase
|
Direct |
23,000
+13.11%
|
$276,000
$12.36 P/Share
|
Nov 03
2023
|
William T Boehm Director |
BUY
Open market or private purchase
|
Direct |
2,000
+7.02%
|
$32,000
$16.05 P/Share
|
Oct 25
2023
|
Douglas Edward Jones Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+21.68%
|
$150,000
$15.17 P/Share
|
Oct 13
2023
|
Jason Warren Lilly Vice President |
SELL
Open market or private sale
|
Direct |
351
-1.3%
|
$5,265
$15.1 P/Share
|
Oct 12
2023
|
James P Tobin Director |
BUY
Open market or private purchase
|
Direct |
3,000
+12.82%
|
$45,000
$15.19 P/Share
|
Oct 11
2023
|
William T Boehm Director |
SELL
Open market or private sale
|
Direct |
2,591
-9.56%
|
$38,865
$15.61 P/Share
|
Oct 11
2023
|
Jason Warren Lilly Vice President |
SELL
Open market or private sale
|
Direct |
1,917
-6.88%
|
$28,755
$15.69 P/Share
|
Oct 11
2023
|
David H. Naemura CFO |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$150,000
$15.03 P/Share
|
Aug 18
2023
|
William T Boehm Director |
SELL
Open market or private sale
|
Direct |
1,500
-5.77%
|
$33,000
$22.59 P/Share
|
Aug 18
2023
|
William T Boehm Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+5.45%
|
$22,500
$15.62 P/Share
|
Apr 25
2023
|
Jason Warren Lilly Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
388
-1.77%
|
$6,208
$16.67 P/Share
|
Last 12 Months Summary
Open market or private purchase | 78K shares |
---|---|
Discretionary transaction | 17.5K shares |
Exercise of conversion of derivative security | 5.02K shares |
Payment of exercise price or tax liability | 906 shares |
---|---|
Open market or private sale | 6.36K shares |